



the IFODS on behalf of Cours St Paul

International and French Oncology Days
Les Journées Franco-Internationales d'Oncologie

Preliminary Program

13-15
October
2021

RIVE MONTPARNASSE

44 bd de Vaugirard
75015 Paris

4th
Edition
Hybrid

President:

Jean-Philippe SPANO - MD, PhD
Paris, France

Comité d'organisation :

Matti Aapro, Jean-Pierre Armand, David Azria, Fabrice Barlesi,
Jean-Yves Blay, Anne Charrasse, Nadine Dohollou, Rosine Guimbaud,
Nicolas Girard, Joseph Gligorov, Aurélien Gobert, Charles Canova,
Nathalie Laouti-Savariaud, Thierry Lebret, Philippe Maingon,
Jean-Philippe Metges, Mathieu Minsat, Françoise Mornex, Laurence Moureau,
Muriel Paul, Frédérique Penault-Llorca, Edith Perez,
Pascal Pujol, Isabelle Ray-Coquard, Manuel Rodrigues,
Sandra Swain, Agnès Tallet, Thierry Toubiana,
Idriss Troussier, Jean-Jacques Zambrowski



International Medical Events
I.M.E., la marque P.C.O du Groupe Equatour

38 rue de Laborde - 75008 Paris

Tel. : 00 33 (0)1 41 04 04 04 Fax : 00 33 (0) 1 41 04 04 11

Join us on

Linked  

www.ifods.com



Dear Friends,

We are pleased and honored to report that the Fourth Edition of IFODS will be held **in Paris from 13-15 October 2021**. The Third Edition was a tremendous success, with over 210 participants in attendance and 450 in virtual. The quality talks and sessions have received such positive feedback across the board that we have decided to go ahead with our plans to create a major national oncology conference, in close collaboration with national oncology societies and leading international experts.

Meanwhile, we must continue to promote this conference to grow attendance year on year and to provide sustained excellence in oncology training. This is why we are moving the event to a more central and accessible location in Paris. This venue is even more conducive to dialogue and communication, everything being on the same floor, whether it be the central forum where partners and participants can interact, the meeting rooms all around, or the auditorium for plenary sessions.

We are looking forward to welcoming you at the **Rive Montparnasse** business center, which is very close to Montparnasse train station.

As in previous editions, the French Cancer Society (SFC) is working alongside IFODS to organize a special opening session on the **Future of Oncology**, with contributions from scientists and young oncologists. Institution like EACR is also expected to provide renewed support.

IFODS seeks to promote the efforts of all who fight against cancer, by sharing the best and latest developments in oncology as well as best practice guidelines. In line with this objective, IFODS is delighted to welcome patients and patient groups to its Science Committee meetings and to a number of sessions. The conference will provide these honored guests with opportunities to learn about therapeutic approaches and to confer with healthcare providers.

France is a key player within the global field of oncology and, as such, deserves a world-leading conference on a par with its excellent level of care.

Please join us in Paris from **13-15 October 2021**, for the Fourth Edition of IFODS. As always, pride of place will go to training, dialogue, sharing and excellence in science, in a warm and friendly environment.

Thank you in advance for your support and participation.

We hope to see you there!

With kind regards,

Jean-Philippe SPANO
President of the IFODS Science Committee

SCIENTIFIC SYMPOSIUM ON PROGRAM

Scientific Symposia are sessions during which some of the world best experts will, upon invitation, address different issues related to a specific topic. Each scientific symposium will end with a round table discussion and Q & A with the audience.

WEDNESDAY 13th OCTOBER

10:00-10:30 AM

► **PLENARY ROOM**

OPENING SESSION : Jean-Philippe SPANO

► 10:30 AM-12.30 PM

LA SEINE (PLENARY) • HIGHLIGHTS FITI*

SESSION (*International Meetings Update*)

Joseph Gligorov, Charles-Henri Canova,
Gérard Milano

► 12:30-1:30 PM: **SYMPOSIUM**

With the Support of PFIZER

Metastatic breast cancer RH+/HER2-: from clinical trials to real-life data.

Pr Jean-Philippe Spano

- Which patients benefit from CDK 4/6 inhibitors in the first line? Pr William Jacot
- For whom and when to consider PARP inhibitors? Dr Audrey Mailliez

► 1:30-2:00 PM: **LUNCH BOX**

► **THE FUTURE OF ONCOLOGY (Basic Science)**

LA SEINE (PLENARY) • 02:00-04:00 PM

Under the aegis of SFC, EACR and AACR

President: Manuel Rodrigues
Chairpersons: Jacques-Olivier Bay, Jean-Pierre Armand & Marie Dutreix

2:30- 3:00 PM: The avoidable causes of cancer in France: Pr Catherine Hill, Epidemiologist at Gustave Roussy Institute

3:00- 3.30 PM: Augmented reality in surgery: Pr Nicolas Bourdel, Gynecological surgeon at the Clermont-Ferrand University Hospital, CEO & Founder of SurgAR

3.30- 4:00 PM: Antibody Drug Conjugates: recent developments and future prospects:

Pr Charles Dumontet, Researcher at the Lyon Cancer Research Center and co-founder of 3 startups

4:00- 4.30 PM: Future prospects in oncogeriatric care organization: Pr Laure De Decker, Head of the service of oncogeriatrics at the Nantes University Hospital and President of the SOFOG

• 04:00-04:30 PM: pause / visite sur les stands / break

► **AWARDS CEREMONY**

LA SEINE (PLENARY) • 04:30-05:30 PM

- **THESIS** on behalf of AERIO, SFC & SFRJO
- **CLAUDE JACQUILLAT** on behalf of SFC
With the Support of BMS

Honorary Presidents: Edith Perez & Sandra Swain

► **PRECISION MEDICINE IN GYNECOLOGICAL CANCERS**

Under the aegis of SFMP

MISSISSIPI • 10:30 AM-1:30 PM

President: Pascal Pujol

10:30 AM-12:00 PM: PRECISION MEDICINE IN GYNECOLOGICAL CANCERS: FROM DEVELOPMENT TO CLINICAL PRACTICE

With the Support of GSK

- The place of immunotherapies in the management of endometrial cancer. Florence Joly (or Alexandra Leary)

WEDNESDAY 13th OCTOBER

- Management of cervical cancer: news from SGO and ASCO 2021. **Patricia Pautier**
- Looking back on 5 years of advances / therapeutic revolutions in ovarian cancer. **Thibaut de la Motte Rouge**

12:00-1:30 PM: REVIEW OF THE NEWS OF PARPI IN DIFFERENT TUMORS

With the Support of MSD-ASTRAZENECA

- Clinical and molecular orientation of personalized treatment in ovarian cancer. **Isabelle Ray-Coquard**
- Prostate cancer and PARPi. **Karim Fizazi (TBC)**
- Future place of PARPs in the adjuvant treatment of high-risk localized breast cancer. **Suzette Delaloge**

➤ 1:30-2:00 PM: **LUNCH BOX**

➤ CONTINUING EDUCATION

MISSISSIPI • 02:00-04:00 PM

Under the aegis of SOFOM & AERIO

Presidents: **Stéphane Culine, Joseph Gligorov, Muriel Dahan**

➤ POSTERS SESSION

➤ LES PARAMEDICAUX SOIGNER À L'HEURE DU NUMÉRIQUE

ST LAURENT • 02:00-04:00 PM

Under the aegis of AFIC

President: **Pascale Dielenseger**

Chairpersons: **Elianne Dubois, Nicole Rama, Monique Debard, Marie Laure de Botton**

- Utilisation des casques de réalité virtuelle lors des soins
- App de suivi des patients sous thérapie orale
- Lien ville –hôpital : un « petit robot » pour rester en contact
- Expérience de Formation des professionnels de santé via un Escape game

• 04:00-04:30 PM: pause / visite sur les stands / break

THURSDAY 14th OCTOBER

▷ CONSENSUS AND GUIDELINES FOR BREAST CANCER ⁽¹⁾

Session dedicated to Pr Angelo Di Leo

LA SEINE (PLENARY) • 09:00-12:30 AM

Under the aegis of St Paul & AROME

Presidents: Frédérique Penault Llorca, Moïse Namer, Marc Spielmann, Yazid Belkacemi, Joseph Gligorov

09:00- 10:00 AM: **NEW STANDARDS IN TN DISEASES**

09:00-09:40: Early TNBC

With the Support of MSD

- 09:00-09:20: Are ICT part of the standard neoadjuvant treatments for TNBC ? **Jean-Yves Pierga** (Institut Curie)

- 09:20-09:40: Is adjuvant PARPi treatment the new standard for all BRCAmut patients in adj setting ? **Suzette Delaloge** (Gustave Roussy)

With the Support of GILEAD

09:40-10:00: Advanced TN disease

- 09:40-10:00: New options for metastatic TNBC hopes and hypes ? **Edith Perez** (Mayo clinic)

10:00- 11:30 AM: **NEW STANDARDS IN HR POSITIVE DISEASES**

- 10:00-10:30: De-escalating chemo in the adjuvant setting who, how, when ? **Olivier Tredan** (Centre Léon Bérard)

10:30-11:00: COFFEE BREAK

- 11:00-11:30: Endocrine treatment options after CDK4/6 progression in first line HR+ MBC ? **Elise Deluche** (Limoges)

▷ 11:30-12:30 PM:

LA SEINE (PLENARY) • SYMPOSIUM

With the Support of DAIICHI SANKYO & ASTRAZENECA

Management of HER2+ Breast Cancer : current and emerging therapies

- Welcome & introduction. **Jean-Philippe Spano**
- HER2+ Early Breast Cancer : advances and implications for the metastatic phase. **Thierry Petit**

- HER2+ Metastatic Breast Cancer : recent progress and challenges. **Barbara Pistilli**
- Round-table / Questions from audience

▷ 12:30-1:30 PM:

LA SEINE (PLENARY) • SYMPOSIUM

*With the Support of NOVARTIS
 Cancer du sein métastatique RH+*

▷ 1:30-2:00 PM: **LUNCH BOX**

▷ LA LEÇON DES IFODS

LA SEINE (PLENARY) • 02:00-02:30 PM

Chairpersons: **Edith Perez & Frédérique Penault-Llorca**
 Speaker: **Lisa Derosa**
 ONCOVID19

▷ CONSENSUS AND GUIDELINES FOR BREAST CANCER ⁽²⁾

Session dedicated to Pr Angelo Di Leo

LA SEINE (PLENARY) • 02:30-04:30 PM

Under the aegis of St Paul & AROME

Presidents: Frédérique Penault Llorca, Moïse Namer, Marc Spielmann, Yazid Belkacemi, Joseph Gligorov

02:30- 03:30 PM: **NEW STANDARDS IN HER2 POSITIVE DISEASES**

- 02:30-03:00: Better and less toxic in low-risk HER2 positive EBC treated in the adjuvant setting. **Sandra Swain** (Georgetown University School of Medicine)

- 03:00-03:30: Decision factors for treatment choice in HER2 positive MBC. **Thierry Petit** (ICANS)

▷ 3:30-04:30 PM:

LA SEINE (PLENARY) • SYMPOSIUM

With the Support of SEAGEN

▷ SFCO - GINECO & SFMPP SESSION CONSENSUS TREATMENT OF GENOMICS AT THE CLINIC

LA SEINE (PLENARY) • 04:30-05:30 PM

Under the aegis of SFCO, GINECO GROUP & SFMPP

Chairpersons: **Anne-Claire Hardy-Bessard, Jérôme Alexandre, Pascal Pujol, Jean-Marc Classe**

- Update and trials in endometrial cancer: **Elsa Kalbacher**

- Saint Paul's ovarian cancer guidelines: **Manuel Rodrigues**

- Genomic and ovarian cancer: **Guillaume Bataillon**

- Main trials in gynecologic cancer surgery (OVHIPEC2, CIPPI, CHIPOR, CHRONO, SÉNTICOL 3...): **Pierre-Emmanuel Colombo**

5:30-5:45 PM: pause / visite sur les stands / break

▷ CONSENSUS AND GUIDELINES FOR GI TUMORS

MISSISSIPI • 09:00-12:30 AM

Under the aegis of Prodigé Group, UNICANCER GI, GERCOR, FFCD

Presidents: **Emmanuelle Samalin, Thierry André, Christophe Louvet, Pierre Michel**

THURSDAY 14th OCTOBER

Chairpersons: **Christophe Louvet, IMM Paris et Emmanuelle Samalin, ICM Montpellier**

9:00-10:30 AM: OESOPHAGEAL AND GASTRIC CANCER

- Neoadjuvant therapy for Gastroesophageal adenocarcinoma: **Romain Cohen**, APHP, Hôpital Saint-Antoine
- Metastatic gastroesophageal adenocarcinoma: current status and perspectives: **Jean-Philippe Metges**, CHU de Brest
- Squamous cell carcinoma of the Esophagus : Strategies for metastatic disease: **Camille Evrard**, CHU de Poitiers

10:30 – 11:00 AM: pause / visite sur les stands / break

11:00-12:30 AM: Chairpersons: **Thomas Aparicio**, APHP, Hôpital Saint Louis et **Thierry André**, APHP, Hôpital Saint Antoine

HEPATOCELLULAR CARCINOMA:

- Locoregional therapy: **Julien Edeline**, Centre Eugène Marquis, Rennes
- Systemic treatment: **Philippe Merle**, CHU La Croix Rousse, Lyon

LOCALLY ADVANCED RECTALADENOCARCINOMA :

- Total neoadjuvant therapy: **Ludovic Evesque** et **Eric François**, Centre Antoine Lacassagne, Nice
- How to optimize current strategies: **Antoine Brouquet**, APHP, Le Kremlin-Bicêtre

➤12:30 AM-02:00 PM

MISSISSIPI • LUNCH/DEBATE

With the Support of PIERRE FABRE

Metastatic colorectal cancers (mCRC) : Personalized treatments for BRAFV600E mutation

- Session 1: mCRC: molecular targets of interest in 2021, speaker: **Romain Cohen**
- Session 2: Targeting BRAF in the BRAFV600E mutated mCRC, speaker: **Emmanuelle Samalin**
- Session 3: Optimization of Encorafenib treatment in mCRC, speaker: **Camille Evrard**

➤ CONSENSUS AND GUIDELINES FOR DERMATOLOGY

MISSISSIPI • 02:30-05:00 PM

President: **Barouyr Baroudjian, Céleste Lebbe (TBC)**
 Chairpersons: **Donia Lassoued & Stéphane Barete**

- What's the best therapeutic sequence in metastatic melanoma ? **Lise Boussemart**
- Adjuvant and neoadjuvant melanoma management. **Caroline Dutriaux**
- Melanome brain metastasis: what's new ? (TBD)
- Melanoma management: what are the current trials and the future treatments. **Jérémy Lupu**

- Advanced basal cell and squamous cell cutaneous carcinoma: what's new, **Nicole Basset Seguin**

➤ CONSENSUS AND GUIDELINES FOR UROLOGY

ST LAURENT • 09:00-12:30 AM

Under the aegis of AFU

President: **Georges Fournier**

09:00 AM: opening session. **Georges Fournier**, President de l'AFU

Chairpersons: **Arnaud Méjean, Antoine Faix**

09:10- 10:30 AM

- Prostate cancer screening: what is new in 2021?: **Georges Fournier**

- Re-irradiation for intra prostatic recurrence using MRI-RT: **David Azria**

- Adjuvant treatment for muscle invasive bladder tumour: **Thierry Lebret**

10:30 – 11:00 AM: pause / visite sur les stands / break

Chairpersons: **Georges Fournier, David Azria**

11:00-12:00 AM

- After pelvic radiotherapy or surgery: Sexuality without erection: **Antoine Faix**
- Reductive nephrectomy in the area of immunotherapy: **Arnaud Méjean**
- The best combo for first line therapy for metastatic renal carcinoma: **Emeline Colombat**
- Conclusions: key messages. **Georges Fournier**

➤ POSTERS SESSION

10:30-11:00 AM: pause / visite sur les stands / break

➤1:30-2:00 PM: **LUNCH BOX**

➤ CONSENSUS AND GUIDELINES FOR ADAPTIVE RADIOTHERAPY

ST LAURENT • 02:30-05:00 PM

Under the aegis of SFRO & SFRJO

President: **Philippe Giraud**

Chairpersons: **David Azria, Florence Huguet, Philippe Maingon, Mathieu Minsat, Françoise Mornex**

2:30-3:00 PM: CT-guided adaptive radiotherapy **Julien Welmant**

3:00-3:30 PM : MR-guided adaptive radiotherapy, IPC Marseille, **Marguerite Tyran**

3:30-4:00 PM : Return on operating experience (REX): The radiotherapist's perspective, CGFL Dijon, **Jean-Luc Géricault**

4:00-4:30 PM: Functional imaging guided adaptive radiotherapy, **Sébastien Thureau**

4:30-5:00 PM : Main indications: State of the Art, **Eleonor Rivin Del Campo**

5:00-5:30 PM: pause / visite sur les stands / break

FRIDAY 15th OCTOBER

▷ CONSENSUS AND GUIDELINES FOR LUNG CANCER ⁽¹⁾

LA SEINE (PLENARY) • 09:00-12:30 AM

Under the auspices of our respective groups: IFCT, Oncology Group/SPLF

Présidents: Frances Shepherd, Fabrice Barlesi

Chairperson(s): Françoise Mornex, Pierre Mordant

STAGE I-III NSCLC

9:00 AM: SABR - state of the art, **Antoine Levy**

9:20 AM: Perioperative immunotherapy, **Marie Wislez**

9:40 AM: Postoperative TKIs in EGFRmutated NSCLC patients, **Frances Shepherd**

10:10 AM: Non resectable stage III NSCLC– state of the art, **Françoise Mornex, Anna Wrona**

10:30-11:00 AM: pause / visite sur les stands / break

STAGE IV NSCLC WITH NO DRIVER ALTERATION

11:00 AM: Mono-immunotherapy. (TBD)

11:20 AM: Double immunotherapy. **Anne-Claire Toffart**

11:40 AM: Chemo-immunotherapy. **Etienne Giroux-Leprieur**

11:40 AM: Which treatment after 1st line immunotherapy or chemo-immunotherapy? **Laurent Greillier**

▷ POSTERS SESSION

▷ 12:30PM-1.30 PM

LA SEINE (PLENARY) • SYMPOSIUM

With the Support of ASTRAZENECA

Latest advances in the treatment of EGFRm NSCLC: paradigm shift from early stages

• Clinical progress in the adjuvant treatment of resectable EGFRm NSCLC. **Dr David Planchard**

• Surgeon's role in patient's path considering latest treatment progresses. **Dr Agathe Seguin**

• Which diagnostic toolbox for the thoracic oncologist tomorrow ? **Pr Paul Hofman**

• Q&A

▷ 1:30-2:00 PM: **LUNCH BOX**

▷ CONSENSUS AND GUIDELINES FOR LUNG CANCER ⁽²⁾

LA SEINE (PLENARY) • 02:00-03:30 PM

Under the auspices of our respective groups: IFCT, Oncology Group/SPLF

Présidents: **Virginie Westeel, Nicolas Girard**

Chairperson(s): **TBD**

STAGE IV NSCLC WITH ADDICTIONS

2:00 PM: Driver alterations and available first-line targeted treatments, **Alexis Cortot**

2:30 PM: EGFRmut NSCLC: treatment post-osimertinib, **Nicolas Girard**

2:50 PM: ALK+: which treatment after first-line TKI? **Michaël Duruisseaux**

3:10 PM: KRASmutated patients, **Pascale Tomasini**

▷ 03:30-04:30 PM

▷ POSTERS AWARD

▷ LA PAROLE EST AUX PATIENTS

ST LAURENT • 09:00-10:30 AM

Sous l'égide d'Europa Donna, Life is Rose, Rose Magazine, L'UDP

Presidents: **Nathalie Savariaud, Jean-Jacques Zambrowski, Maryline Baranes, Gary Rodin, Maryline Rébillon**

COMMENT LA PANDÉMIE COVID-19 A MODIFIÉ LA QUALITÉ DE VIE DES PATIENTS ACCOMPAGNÉS PAR LES ASSOCIATIONS. QUELLES LEÇONS EN TIRER ?

10:30-11:00 AM: pause / visite sur les stands / break

▷ CONSENSUS AND GUIDELINES FOR SARCOMA

ST LAURENT • 11:00-12:30 AM

Under the aegis of GSF-GETO & NET-SARC

Chairperson(s): **Axel Lecesne, Jean-Yves Blay**

• Immunotherapy: **Armelle Dufresne**

• The natural history and treatment of desmoid tumors: **Nicolas Penel**

• The natural history and treatment of retroperitoneal sarcomas: **Sylvie Bonvalot**

• Molecular medicine for sarcomas: Multisarc and beyond. **Antoine Italiano**

• Conclusion

FRIDAY 15th OCTOBER

▷ HEART VESSELS AND CANCERS

ST LAURENT • 02:00-03:30 PM

Chairperson(s): **Joe-Elie Salem, Francis Cajfinger**

- Carcinoid heart: Diagnosis and management: **Stéphane Ederhy**
- QT prolongation and arrhythmias under anticancer drugs: **Paul Gougis**
- Anticancer and risk of thrombosis: **Corinne Frere**

4:30-5:00 PM: pause / visite sur les stands / break

11:00-12:30 AM

PART II : "STARTUP PITCH"

1 - Selection of 8 projects following the call for applications - startups which may be: biotech, medtech, esanté, diag, IA ... 7mn per pitch + 3mn Q&A

▷12:30PM-1.30 PM: **LUNCH BOX**

▷ BIOTECH IN ONCOLOGY

MISSISSIPI • 09:00-12:30 PM

Under the aegis of Gustave Roussy Transfert, Cancer Campus and Angels Santé

Chairperson(s): **Jean-Pierre Armand** (Gustave Roussy, Villejuif), **Stéphane Loze** (Angels Santé, Paris)

9:00- 10:30 AM

PART I : "CROSSED PERSPECTIVES ON THE PATH OF 3 FRENCH BIOTECHS IN ONCOLOGY! "

- 1 - THE CREATION: ONE BIOSCIENCES from academic research to the creation of a startup
Céline Vallot, head of the CNRS team "Dynamics of Epigenetic Alterations in Cancer" at Institut Curie & co-founder of the startup ONE BIOSCIENCES
Amaury Martin, Director Innovation & Development - Curie Institute

2 - FINANCING AND DEVELOPMENT: The example of AGLAIA

- Caroline Robert**, Head of Dermatology Gustave Roussy & co founder of the startup AGLAIA
Matthieu Coutet, Managing Partner at Advent France Biotechnology (venture capital company specializing in life science and lead investor of AGLAIA)

3 - THE CHANGE OF SCALE! The example of INNATE Pharma

- Yannis Morel**, researcher in immunology, executive vice president & business development of Innate Pharma (within Innate Pharma since almost its creation in 1999)
Mondher Mahjoubi, Chairman of the Executive Board CEO of Innate Pharma

10:30-11:00 AM: pause / visite sur les stands / break

▷ INTERACTIVE WEBCONFERENCE; SURGERY FOR BONE METASTASES: WHAT COMPLICATIONS? WHAT ARE THE RISK FACTORS?

MISSISSIPI • 02:00-03:00 PM

Sous l'égide du groupe GEMO

Présidents: **Marie-Hélène Vieillard & Frédéric Clarençon**

Chairperson(s): **Laetitia Morardet, Matti Aapro**

4:30-5:00 PM: pause / visite sur les stands / break



SUBMISSION GUIDELINES

- **Abstracts** have to be submitted electronically and in English
- **Abstracts** received after the deadline (September 10th, 2021) will not be considered
- Supply as much information as possible: the precise subject of study, methods used where appropriate, summary of results obtained, conclusion
- As it is assumed that original work will be presented, no bibliographic references are necessary
- Selected **abstracts** will be published in the abstract book exactly as you submitted it. Therefore, proofreading is essential, no modification will be possible after submission.
- Your **abstract** should not contain accents or any other invalid character, which would not be part of the English alphabet.
- Your **abstract's** text should not exceed 3,000 characters (excluding spaces)
- The main author (presenter) confirms that all authors are aware of and agree to the content of the abstract and support of the data presented. By submitting his abstract, the author allows the IFODS to publish and distribute or sell his abstract as part of the Abstract Book, which may be distributed on paper.
- All selected **abstracts** will be published in the abstract book. Papers accepted for IPOSTER presentation will be displayed during poster sessions.
- Acceptance or rejection of the paper by the Scientific Committee will be notified by email to the main author (presenter) by September 14th, 2021
- Only persons whose registration is complete will be able to present their **abstracts**
- IPOSTERS will be awarded or encouraged: a special jury will select the three best posters and their authors will receive IFODS Poster Award and a cheque of 500€ each.

Registration (Allows to access all satellite meetings of the IFODS)

REGISTRATION FEES (in Euros)	Regular Registration
From Nov. 15 th 19 to June. 15 th 2021	☐ 500 € HT
From June 16 th 2021 and on site	☐ 600 € HT
Student registration fees <i>(The participation of student is conditioned by the full coverage of their hospitality costs)</i>	☐ 100 € HT

WAY OF REGISTRATION

Online Registration: secure online registration and payment by credit card via the website www.ifods.com

Registration will be validated only with payment by credit card (Visa, Mastercard).

Registration Form sent by Fax or Mail:

you can download the registration form on the website and send it duly completed to the Organisation Committee.

Registration will be validated only with payment attached or credit card information completed.

Cancellation Policy / Before July 10th, 2021: 50% cancellation fees / From July 11th, 2021: no refund



I.M.E, la marque P.C.O
du Groupe Equatour

International Medical Events (IME)

38 rue de Laborde - 75008 Paris- France - Email: infos@im-events.com

Organisation Committee

Contact : Valérie CAILLON : Tel : + 33 1 41 04 04 35 - Fax : +33 1 41 04 04 11 Email: valerie.caillon@im-events.com

Travel Information & Accommodation

Contact : Mathilde MANGIN : Tel : + 33 1 41 04 04 31 - Fax : +33 1 41 04 04 11

Email: mathilde.mangin@im-events.com

CONGRESS LOCATION RIVE MONTPARNASSE

LOCALISATION ET ACCÈS

44 Boulevard de Vaugirard,
Paris 15^e




Lignes 4, 6, 12 et 13
(Montparnasse, Gait e)

BUS

Lignes n  28, 58, 91, 92, 94, 95,
96, 88

PARKING

Parking Pasteur
Interparking



I.M.E, la marque P.C.O du Groupe Equatour

Infos@im-events.com

Tel. : 00 33 (0) 1 41 04 04 04 / Fax : 00 33 (0) 1 41 04 04 11



SKYTEAM
GLOBAL MEETINGS

**WITH SKYTEAM, YOUR GLOBAL MEETING
IS SIMPLE TO ORGANISE AND EVEN EASIER TO GET TO.**

Whether you are the organiser or the participant, the Global Meetings Program allows you to benefit from the expertise of SkyTeam's network covering over 1,000 destinations worldwide. Via the online portal, not only can participants obtain discounted travel, but flights and connections are made more convenient. Organisers can also take advantage of an online solution especially designed to meet their needs, including a productivity reward program. Additionally, we provide you with a communications kit and one point of contact to help manage your event. Visit our website www.skyteam.com/globalmeetings



AIR FARE DISCOUNT - Event ID : 37 494 AF

SkyTeam Global Meetings Agreement - This Agreement is entered into by and among member airlines of the SkyTeam Alliance and EQUATOUR. The airlines of SKYTEAM, Official Alliance Network for the IFODS 2021, offer attractive airfares for participants. SKYTEAM comprises 19 leading international airlines serving 1000 destinations in 187 countries with over 15 000 flights daily.

GLOBAL MEETINGS PROGRAM - TICKETS PURCHASING

The Discount Agreement will be for travel between october 06th through 22nd 2021.

To benefit from these special offers, link up with <http://globalmeetings.skyteam.com> and quote the Identifier Code 36 189 AF Tickets purchased on the following Carriers are eligible for the SkyTeam Global Meetings programme:

Aeroflot, Aerolneas Argentinas, Aerom xico, Air Europa, Air France, Alitalia, China Airlines, China Eastern, China Southern, Czech Airlines, Delta Air Lines, Kenya Airways, KLM Royal Dutch Airlines, Korean Air, Middle East Airlines, Saudia, TAROM, Vietnam Airlines and Xiamen Air.

To book your travel now, visit www.skyteam.com/GlobalMeetings and enter your Event ID, 37 494 AF

Through this site you can also access the schedules of all SkyTeam partners to plan your flights on the airline of your choice.



International Medical Events - IME
spécialiste de la gestion
de congrès médicaux

 00 33 (0)1 41 04 04 04

 infos@im-events.com

IME, la marque P.C.O du Groupe Equatour

